CN113288986A - 一种治疗非酒精性脂肪肝的中药组合物及其制备方法 - Google Patents
一种治疗非酒精性脂肪肝的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN113288986A CN113288986A CN202110497642.7A CN202110497642A CN113288986A CN 113288986 A CN113288986 A CN 113288986A CN 202110497642 A CN202110497642 A CN 202110497642A CN 113288986 A CN113288986 A CN 113288986A
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- fatty liver
- liver disease
- alcoholic fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 75
- 241000132012 Atractylodes Species 0.000 claims abstract description 7
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract description 7
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 7
- 241000545744 Hirudinea Species 0.000 claims abstract description 7
- 241000255789 Bombyx mori Species 0.000 claims abstract description 6
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 6
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 6
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 6
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 6
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 6
- 244000299790 Rheum rhabarbarum Species 0.000 claims abstract description 6
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 6
- 241000923606 Schistes Species 0.000 claims abstract description 6
- 229910001919 chlorite Inorganic materials 0.000 claims abstract description 6
- 229910052619 chlorite group Inorganic materials 0.000 claims abstract description 6
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 5
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 5
- 235000020240 turmeric extract Nutrition 0.000 claims abstract description 5
- 229940052016 turmeric extract Drugs 0.000 claims abstract description 5
- 239000008513 turmeric extract Substances 0.000 claims abstract description 5
- 240000001341 Reynoutria japonica Species 0.000 claims abstract description 4
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 4
- 235000011477 liquorice Nutrition 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 5
- 244000153955 Reynoutria sachalinensis Species 0.000 claims description 2
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims description 2
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 claims 1
- 240000007164 Salvia officinalis Species 0.000 claims 1
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 claims 1
- 229940051810 licorice root extract Drugs 0.000 claims 1
- 235000020725 licorice root extract Nutrition 0.000 claims 1
- 244000132619 red sage Species 0.000 claims 1
- 235000005412 red sage Nutrition 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 23
- 210000004369 blood Anatomy 0.000 abstract description 23
- 230000003908 liver function Effects 0.000 abstract description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 abstract description 8
- 108010082126 Alanine transaminase Proteins 0.000 abstract description 8
- 108010003415 Aspartate Aminotransferases Proteins 0.000 abstract description 8
- 102000004625 Aspartate Aminotransferases Human genes 0.000 abstract description 8
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 abstract description 8
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 abstract description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 8
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 abstract description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 7
- 108010023302 HDL Cholesterol Proteins 0.000 abstract description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract description 4
- 108010028554 LDL Cholesterol Proteins 0.000 abstract description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 4
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract description 4
- 235000012000 cholesterol Nutrition 0.000 abstract description 4
- 150000002632 lipids Chemical class 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 12
- 206010062717 Increased upper airway secretion Diseases 0.000 description 10
- 208000026435 phlegm Diseases 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 244000163122 Curcuma domestica Species 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000011021 lapis lazuli Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 150000004291 polyenes Chemical class 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 241000255791 Bombyx Species 0.000 description 2
- 235000014375 Curcuma Nutrition 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 229940083040 vitamin E pill Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Insects & Arthropods (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Animal Husbandry (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗非酒精性脂肪肝的中药组合物,所述中药组合物由包括如下重量份的原料制成:姜黄提取物12份、大黄提取物9份、白术提取物10份、绞股蓝提取物10份、葛根提取物10份、荷叶提取物10份、泽泻提取物10份、丹参提取物10份、虎杖提取物15份、僵蚕提取物10份、水蛭提取物3份、礞石提取物10份、甘草提取物6份;及其制备方法和用途。该组合物能有效缓解非酒精性脂肪性肝病患者的临床症状,改善患者肝功能,降低患者丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、γ‑谷氨酰转肽酶(GGT)以及血脂中的甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白(LDL‑C)的含量,提高高密度脂蛋白(HDL‑C)含量,有效改善血脂,缓解病情迁延并向愈转化。
Description
技术领域
本发明属于中药技术领域,具体涉及一种治疗非酒精性脂肪肝的中药组合物及其制备方法。
背景技术
非酒精性脂肪性肝病早期无明显症状,进展慢,但疗程久,易迁延,治疗相对复杂,若不及时控制最终可导致肝纤维化、肝硬化,甚至肝细胞癌。
非酒精性脂肪性肝病的发病机制至今尚未研究阐明,目前临床观点多认为其发生主要以“二次打击”学说为基础,涉及胰岛素抵抗、瘦素抵抗、氧化应激、内质网应激、肠道微生物态、自噬等方面。非酒精性脂肪性肝病的防治,至今未找到理想方法。现代医学对本病的治疗主张控制饮食,加强运动并配合药物治疗,药物治疗方面目前临床未找到特效药,大多常采用胰岛素增敏剂、降脂、保肝等药物,主要针对胰岛素抵抗、氧化应激、炎症及纤维化等方面进行相关治疗。
发明内容
本发明的第一个目的是为了解决上述问题,提供一种治疗非酒精性脂肪肝的中药组合物,对非酒精性酒精肝具有较好的疗效,无明显的副作用。
本发明的第二个目的是提供上述中药组合物的制备方法。
本发明的第三个目的是提供上述中药组合物的用途。
本发明的目的通过以下技术方案来具体实现:
一种治疗非酒精性脂肪肝的中药组合物,所述中药组合物由包括如下重量份的原料制成:
姜黄提取物12份、大黄提取物9份、白术提取物10份、绞股蓝提取物10份、葛根提取物10份、荷叶提取物10份、泽泻提取物10份、丹参提取物10份、虎杖提取物15份、僵蚕提取物10份、水蛭提取物3份、礞石提取物10份、甘草提取物6份。
上述中药组合物的制备方法,将姜黄提取物、大黄提取物、白术提取物、绞股蓝提取物、葛根提取物、荷叶提取物、泽泻提取物、丹参提取物、虎杖提取物、僵蚕提取物、水蛭提取物、礞石提取物、甘草提取物混合,即得。
上述中药组合物在制备治疗非酒精性脂肪肝的药物中的应用。
本发明的治疗非酒精性脂肪肝的中药组合物,其中姜黄、大黄,苦寒,行气解郁、通腑化瘀;白术、绞股蓝,益气健脾、化痰降脂;葛根、荷叶、泽泻,升清降浊、调节血脂;丹参、虎杖,养血活血、祛痰解毒;僵蚕、水蛭,祛风化痰、化瘀消癥;礞石,涤痰消食、软坚消痞;甘草,和中解毒,善调诸药。本发明组方的配伍特点:僵蚕、葛根、荷叶升阳中之清阳,姜黄、大黄、礞石降阴中之浊阴。升降出入,内外通和;水蛭破血化癥而不伤气阴,礞石峻涤痰结且可消食导滞,二药为伍,痰瘀同治,与白术、绞股蓝益气健脾而相得益彰;本方集行气疏郁,养血活血,涤痰降脂,通腑化瘀,升清降浊于一炉,共奏健脾化痰,活血祛脂之功。
本发明具有以下有益效果:
本发明提供的治疗非酒精性脂肪肝的中药组合物,是一种安全有效的治疗方剂,能有效缓解非酒精性脂肪性肝病患者的临床症状,改善患者肝功能,降低患者丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、γ-谷氨酰转肽酶(GGT)以及血脂中的甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C)的含量,提高高密度脂蛋白(HDL-C)含量,有效改善血脂,缓解病情迁延并向愈转化,提高患者生活质量,是非酒精性脂肪性肝病患者治疗的新选择。
具体实施方式
以下对本发明的优选实施例进行说明,应当理解,此处所描述的优选实施例仅用于说明和解释本发明,并不用于限定本发明。
实施例中的各味中药提取物的生产厂家为江阴天江药业有限公司,是以单味传统中药饮片为原料,经水提、分离、浓缩、干燥、制粒、包装等工艺制成的颗粒状新型配方单味中药,供中医临床配方使用。
实施例1
一种治疗非酒精性脂肪肝的中药组合物,每剂由以下颗粒型中药提取物组成:
姜黄提取物12g,大黄提取物9g,僵蚕提取物10g,绞股蓝提取物10g,白术提取物10g,葛根提取物10g,荷叶提取物10g,泽泻提取物10g,丹参提取物10g,虎杖提取物15g,水蛭提取物3g,礞石提取物10g,甘草提取物6g。
将各位中药颗粒混合,即得二黄祛脂颗粒,是一种免煎中药颗粒剂。
临床试验
试验对象:纳入对象全部来自于石河子大学医学院第一附属医院2018年9月至2019年11月全国名中医袁今奇传承工作室诊室及肝病专科门诊的非酒精性脂肪性肝病确诊患者,共110例,随机分成治疗组和治疗组,两组患者各55例。
治疗方法:基础治疗均为控制饮食、适当运动、减轻体重并兼服维生素E丸。治疗组患者口服二黄祛脂颗粒,每日1剂,用300ml温开水调匀后分为二等份,于早、晚服用;对照组患者给予口服多烯磷脂酰胆碱胶囊,每次2粒,每日3次。两组治疗时间均为3个月。
评价标准:(1)治愈:肝功能、血脂指标正常,肝脏B超显示脂肪肝表现消失,临床症状体征消失;(2)显效:症状体征基本消失,肝功能、血脂基本正常,肝脏B超显示脂肪肝病情分级下降2个级别(重度转为轻度);(3)有效:临床症状体征、肝功能、血脂有所改善,B超示脂肪肝无明显变化;(4)无效:症状体征无改善,肝功能、血脂及肝脏B超均无明显变化。
临床治疗结果:疗程结束后,两组均未出现不良反应。
治疗组治愈27例,显效14例,有效9例,无效5例,总有效率为90.90%;对照组治愈15例,显效12例,有效9例,无效19例,总有效率为65.45%。两组患者临床疗效比较,差异有统计学意义(P<0.05),治疗组优于对照组。
治疗组治疗后肝功能丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、γ-谷氨酰转肽酶(GGT)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C)均比对照组明显降低,高密度脂蛋白(HDL-C)明显升高(P<0.05)。
丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、γ-谷氨酰转肽酶(GGT);*表示与治疗前后比较,P<0.05;△表示两组与治疗后比较,P<0.05,下同
甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)
以本发明的二黄祛脂颗粒治疗非酒精性脂肪性肝病患者55例,与对照药物多烯磷脂酰胆碱胶囊治疗55例进行比较,在肝功能、血脂及总有效率等方面,二黄祛脂颗粒的疗效均优于多烯磷脂酰胆碱胶囊。
中医讲求整体辩证用药,本发明的用于治疗非酒精性脂肪肝的中药组合物(二黄祛脂颗粒)是根据中医药传统理论,结合现代药理研究,该方组成是经发明人多年临床实践积累的自拟验方,配伍全面,集行气疏郁,养血活血,涤痰降脂,通腑化瘀,升清降浊于一炉,共奏健脾化痰,活血祛脂之功。通过临床研究发现可明显改善非酒精性脂肪性肝病患者的症状,有效缓解病情,可广泛用于临床推广。
以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (3)
1.一种治疗非酒精性脂肪肝的中药组合物,其特征在于,所述中药组合物由包括如下重量份的原料制成:
姜黄提取物12份、大黄提取物9份、白术提取物10份、绞股蓝提取物10份、葛根提取物10份、荷叶提取物10份、泽泻提取物10份、丹参提取物10份、虎杖提取物15份、僵蚕提取物10份、水蛭提取物3份、礞石提取物10份、甘草提取物6份。
2.权利要求1所述的中药组合物的制备方法,其特征在于,将姜黄提取物、大黄提取物、白术提取物、绞股蓝提取物、葛根提取物、荷叶提取物、泽泻提取物、丹参提取物、虎杖提取物、僵蚕提取物、水蛭提取物、礞石提取物、甘草提取物混合,即得。
3.权利要求1所述的中药组合物在制备治疗非酒精性脂肪肝的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110497642.7A CN113288986A (zh) | 2021-05-08 | 2021-05-08 | 一种治疗非酒精性脂肪肝的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110497642.7A CN113288986A (zh) | 2021-05-08 | 2021-05-08 | 一种治疗非酒精性脂肪肝的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113288986A true CN113288986A (zh) | 2021-08-24 |
Family
ID=77321047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110497642.7A Pending CN113288986A (zh) | 2021-05-08 | 2021-05-08 | 一种治疗非酒精性脂肪肝的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113288986A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113633747A (zh) * | 2021-09-28 | 2021-11-12 | 石河子大学 | 一种治疗非酒精性脂肪肝病的中药组合物 |
-
2021
- 2021-05-08 CN CN202110497642.7A patent/CN113288986A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113633747A (zh) * | 2021-09-28 | 2021-11-12 | 石河子大学 | 一种治疗非酒精性脂肪肝病的中药组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101972373B (zh) | 治疗高血压、高血糖、高血脂的中药制剂 | |
CN1485083A (zh) | 甲状腺癌瘤淋巴结胶囊 | |
CN101940716A (zh) | 一种治疗糖尿病肾病的药物 | |
CN111643637B (zh) | 一种防治慢性萎缩性胃炎及胃癌前病变的中药组合物及其制备方法和应用 | |
CN103736018A (zh) | 一种治疗胆结石的药物及其制备方法 | |
CN101843694B (zh) | 一种治疗慢性肝炎的中药 | |
CN1931329A (zh) | 治疗口腔溃疡的药物 | |
CN1167452C (zh) | 治疗艾滋病的药 | |
CN113288986A (zh) | 一种治疗非酒精性脂肪肝的中药组合物及其制备方法 | |
CN102657795A (zh) | 一种促进术后刀口愈合的中药制剂 | |
CN101926903A (zh) | 用于治疗面神经麻痹的中药制剂 | |
CN100579544C (zh) | 一种治疗胆囊炎、胆结石的中药制剂及其制备方法 | |
CN1101199C (zh) | 一种治疗高脂血症的中药胶囊制剂 | |
CN102038827A (zh) | 治疗高血压型糖尿病的中药制剂 | |
CN111494583A (zh) | 一种用于治疗慢性萎缩性胃炎的药物组合物及其制备方法 | |
CN101239140A (zh) | 治疗牛皮癣的中药药物 | |
CN104147270A (zh) | 治疗急性肝炎的中药组合物 | |
CN102614432B (zh) | 一种治疗宫颈炎的中药组合物 | |
CN101966329A (zh) | 一种治疗皮疹的药物 | |
CN101850046B (zh) | 一种治疗慢性肝炎的中药 | |
CN1215873C (zh) | 治疗脂肪肝中药复方制剂及制备方法 | |
CN102166303B (zh) | 一种治疗慢性萎缩性胃炎的中药组合物 | |
CN105833152A (zh) | 一种治疗内分泌失调的中药组合物 | |
CN105663850A (zh) | 一种治疗口腔溃疡的中药组合物 | |
CN104587397A (zh) | 一种治疗内分泌失调的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |